Manhattan West Asset Management LLC Takes $3.20 Million Position in IQVIA Holdings Inc. $IQV

Manhattan West Asset Management LLC purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, Holdings Channel reports. The fund purchased 16,574 shares of the medical research company’s stock, valued at approximately $3,202,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. Apella Capital LLC grew its stake in IQVIA by 5.1% in the 1st quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock worth $211,000 after acquiring an additional 58 shares in the last quarter. Quadrant Capital Group LLC raised its stake in shares of IQVIA by 1.3% during the fourth quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock valued at $1,080,000 after acquiring an additional 60 shares in the last quarter. Private Advisor Group LLC boosted its holdings in shares of IQVIA by 1.0% in the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after purchasing an additional 63 shares during the period. Breakwater Capital Group grew its stake in IQVIA by 3.2% in the second quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock worth $401,000 after purchasing an additional 64 shares in the last quarter. Finally, Keybank National Association OH increased its holdings in IQVIA by 0.7% during the 4th quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock worth $2,052,000 after purchasing an additional 67 shares during the period. Institutional investors own 89.62% of the company’s stock.

Insider Activity

In other news, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. This represents a 19.23% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 12,913 shares of company stock worth $3,098,793. Insiders own 1.70% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on IQV. Mizuho raised their price target on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $241.88.

IQVIA Price Performance

Shares of IQV stock opened at $260.17 on Friday. The stock’s 50-day moving average is $213.32 and its 200 day moving average is $187.52. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $260.40. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The company has a market cap of $42.82 billion, a P/E ratio of 32.28, a PEG ratio of 2.17 and a beta of 1.18.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm’s revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the company posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its board has approved a share repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.